Results 1 to 10 of about 769 (122)

Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. [PDF]

Antimicrob Agents Chemother
Fosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment.
Hodges MR, Hazel S, Kramer WG, van Hoogdalem E-J, van Marle S, Tawadrous M, Jakate A.   +6 more
europepmc   +5 more sources

A phase 1 open label study to assess the human mass balance and metabolite profile of ¹⁴C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participants. [PDF]

Antimicrob Agents Chemother
Fosmanogepix [FMGX; active form manogepix (MGX)], a novel antifungal, is currently being studied for the treatment of invasive fungal diseases caused by Candida spp., Aspergillus spp., and other rare molds.
Hodges MR, Ople E, Evans P, Pantophlet AJ(, Richardson J, Williams D, Tripathy S, Tawadrous M, Jakate A.   +8 more
europepmc   +5 more sources

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]

Drugs, 2021
The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture.
Martin Hoenigl, Rosanne Sprute, Matthias Egger, Amir Arastehfar, Oliver A. Cornely, Robert Krause, Cornelia Lass‐Flörl, Juergen Prattes, Andrej Spec, George R. Thompson, Nathan P. Wiederhold, Jeffrey D. Jenks   +11 more
semanticscholar   +6 more sources

S4.1a Fusariosis: MICs, mono versus combination therapy and fosmanogepix [PDF]

Medical Mycology, 2022
S4.1 Treatment of rare mold infections in 2021: the role of new and old antifungals, September 22, 2022, 10:30 AM - 12:00 PM Fusarium is one of the most clinically prevalent rare molds causing superficial infections such as keratitis in immunocompetent ...
Martin Hoenigl
semanticscholar   +3 more sources

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2023
Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections.
Michael R. Hodges, Eric Ople, Pamela Wedel, Karen Joy Shaw, Abhijeet Jakate, William G. Kramer, Sjoerd van Marle, Ewoud‐Jan van Hoogdalem, Margaret Tawadrous   +8 more
semanticscholar   +4 more sources

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections [PDF]

Antimicrobial Agents and Chemotherapy, 2022
Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broad-spectrum
Teclegiorgis Gebremariam, Yiyou Gu, Sondus Alkhazraji, Eman G. Youssef, Karen Joy Shaw, Ashraf S. Ibrahim   +5 more
semanticscholar   +5 more sources

1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections [PDF]

Open Forum Infectious Diseases, 2023
Background Candida auris (CAU) epidemiology is evolving rapidly. Manogepix is the active moiety of the novel prodrug antifungal fosmanogepix (FMGX), and has broad-spectrum activity against yeasts and moulds, including CAU. Fluconazole (FLC) resistance (R)
Cecília G Carvalhaes, Michael D. Huband, Paul R. Rhomberg, Beth Hatch, Mariana Castanheira   +4 more
semanticscholar   +3 more sources

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

Antimicrobial Agents and Chemotherapy, 2023
Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals.
José A. Vázquez, Peter G. Pappas, Kenneth D Boffard, Fathima Paruk, Paul Bien, Margaret Tawadrous, Eric Ople, Pamela Wedel, Iwona Oborska, Michael R. Hodges   +9 more
semanticscholar   +5 more sources

Successful Use of Fosmanogepix for Treatment of Rare Highly Resistant Cutaneous Fusariosis in a Pediatric Patient With STAT3 Hyper-Immunoglobulin E Syndrome and End-Stage Kidney Disease [PDF]

Open Forum Infectious Diseases, 2023
We describe the successful use of the novel antifungal drug fosmanogepix to treat a chronic case of multidrug-resistant cutaneous Fusarium suttonianum infection in a pediatric patient with STAT3 hyper-IgE syndrome and end-stage kidney disease on ...
Kathryn Goggin, Jackson Londeree, Alexandra F. Freeman, Rouba Garro, Roshan George   +4 more
semanticscholar   +4 more sources

Innovative antifungal strategies to combat drug-resistant Candida auris: recent advances and clinical implications [PDF]

Frontiers in Cellular and Infection Microbiology
Candida auris is an invasive fungal pathogen recognized globally as a significant health threat due to its marked resistance to multiple classes of antifungal agents, including azoles, echinocandins, and polyenes.
Wei Du, Qihui Wang, Min Zhao
doaj   +3 more sources